Documents

  • 67

    Final published version, 1.57 MB, PDF document

DOI

  • Всеволод Геннадьевич Потапенко
  • З. К. Абдулхаликова
  • В. В. Байков
  • М. В. Барабанщикова
  • А. В. Ботина
  • С. Л. Воробьев
  • Н. В. Дорофеева
  • Ю. В. Забутова
  • Н. А. Котова
  • В. В. Козыро
  • Ю. А. Криволапов
  • Е. В. Лисукова
  • Ю. С. Осипов
  • Ю. И. Подманкова
  • В. М. Кравцова
  • Н. С. Лазорко
  • Е. В. Морозова
  • Ю. В. Миролюбова
  • О. В. Небелицкая
  • И. А. Самородова
  • А. В. Серков
  • К. В. Скорюкова
  • Е. Н. Точеная
  • О. В. Шварц
  • В. А. Шуваев
  • А. Г. Эмачагли
  • Н. В. Медведева
Aim. To provide case reports on the course and treatment of aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). Materials & Methods. This paper reports the histories of adult patients with ASM (n = 4) and MCL (n = 2) treated with cytoreduction predominantly at the City Clinical Hospital No. 31 (Saint Petersburg). The patients were 36-61 years of age (median 50 years); there were 4 women and 2 men. Results. All patients showed stable response to cladribine (n = 3), imatinib (n = 2), and combined lenalidomide, elotuzumab, and dexamethasone treatment with subsequent allogeneic hematopoietic stem cell transplantation (n = 1). With a median followup of 124 months (range 55-186 months), 1 ut of 2 MCL patients died due to the concomitant hypereosinophilic syndrome progression and secondary infectious complication. Conclusion. Cladribine therapy in 2 ASM patients and imatinib therapy in 2 MCL patients yielded stable longterm response with good quality of life being maintained. More comparative studies are required for efficacy assessment and optimum sequencing of chemotherapeutic drugs.
Translated title of the contributionTreatment of Aggressive Systemic Mastocytosis and Mast Cell Leukemia. Literature Review and Case Reports
Original languageRussian
Pages (from-to)180-194
Number of pages15
JournalKlinicheskaya Onkogematologiya/Clinical Oncohematology
Volume17
Issue number2
DOIs
StatePublished - 1 Apr 2024

    Research areas

  • KIT gene, cladribine, imatinib, mast cell leukemia, mast cells, mastocytoses, tryptase

ID: 127367208